HVTN Translational HIV Vaccine Early Stage Investigator (ESI) Conference


Registration for this conference has closed. However, if you have questions or want more information, please contact Jenna Udren, Conference Project Manager, at judren@fredhutch.org.



MAY 31 - JUNE 1, 2019 


This year’s conference will include a plenary talk titled, “Key Questions to Move the Field Forward from Preclinical and Clinical Perspectives,” featuring Dan Barouch, MD, PhD and John Mascola, MD.


Dan Barouch

Dan Barouch, MD, PhD

Professor of Medicine, Harvard Medical School
Director, Center for Virology and Vaccine Research, BIDMC
Member, Ragon Institute

John Mascola

John Mascola, MD

Director of the Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, NIH


The HIV Vaccine Trials Network (HVTN) will host the 3rd Translational HIV Vaccine Early Stage Investigator (ESI) Conference May 31-June 1, 2019. This conference will build on topics and skills discussed at previous conferences but is also open to new attendees. This conference is intended for early stage investigators who focus on translational and preclinical HIV vaccine research in non-human primates (NHPs), or clinical HIV vaccine research. Investigators participating in the conference will gain a sense of their ability to contribute widely to the field and support in reaching career milestones. Past attendees have stated that the Conference has increased their skills and knowledge for career development and provided them with a venue to form new collaborations.

To support integration of researchers with backgrounds in translational and clinical HIV research, this conference is being held in concert with the HVTN Full Group Meeting, May 29-31, 2019.

The deadline for registering is April 20, 2019.


Target Audience:

Early stage vaccine scientists who focus on translational, clinical, and preclinical HIV vaccine research in non-human primates (NHPs).

An ESI is defined as a person within ten (10) years of completing their terminal research degree, medical residency, or equivalent.

The HVTN will offer a limited number of travel awards to attend this conference. The deadline for submitting an application for a travel award has ended.  


The conference agenda is now available on the Program page.

Additional Information:

Attendees are strongly encouraged to participate in the HVTN Full Group Meeting (FGM). Participation in the FGM will provide attendees further opportunities to expand their knowledge of HIV vaccine science and to continue to develop professional networks. More information about the HVTN FGM can be found here.

Contact Information:

For questions, please contact Conference Project Manager:

Jenna Udren
(206) 667-6712




Funding for this conference was made possible in part by 1 R13 OD024033-01 from the Office of Research Infrastructure Programs (ORIP). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government